Use of 68Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors

Raymond Andrew LeBlanc; Umesh D Oza; Ryan Hayden; Hanna Fanous

doi:10.1080/08998280.2019.1678338

Use of ⁶⁸Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors

Proc (Bayl Univ Med Cent). 2019 Nov 4;33(1):51-52. doi: 10.1080/08998280.2019.1678338. eCollection 2020 Jan.

Authors

Raymond Andrew LeBlanc¹, Umesh D Oza¹, Ryan Hayden¹, Hanna Fanous¹

Affiliation

¹ Department of Radiology, Baylor University Medical CenterDallasTexas.

Abstract

Neuroendocrine tumors (NET), such as insulinomas and carcinoid tumors, can be challenging to diagnose since patients often present with vague symptoms. Adding to the challenge, these tumors are often occult on typical cross-sectional imaging modalities. Because of these challenges, there has been an increase in the utilization of radiopharmaceuticals that take advantage of specific receptors expressed by NET. Among the multiple radiopharmaceuticals that can be used, ⁶⁸Ga DOTATATE is emerging as the most sensitive and specific imaging agent. We present a case where ⁶⁸Ga DOTATATE was used to diagnose a well-differentiated neuroendocrine tumor.

Keywords: 68Ga DOTATATE; Carcinoid; F-18 fludeoxyglucose; neuroendocrine tumors; positron emission tomography/computed tomography.

Publication types

Case Reports